ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Centric Brands Inc

Centric Brands Inc (CTRC)

0.1608
0.00
(0.00%)
At close: July 30 4:00PM
0.1608
0.00
( 0.00% )

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.1608
Bid
0.19
Ask
0.20
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.1608
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

CTRC Latest News

Moderna Set to Join S&P 500

Moderna Set to Join S&P 500 PR Newswire NEW YORK, July 15, 2021 NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the...

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized My...

– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as...

Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Honeywell International Inc. (Nasdaq: HON), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX...

AstraZeneca Says $39 Billion Alexion Deal Set for Completion After UK Clearance -- Update

By Adria Calatayud AstraZeneca PLC said Wednesday that its $39 billion acquisition of Alexion Pharmaceuticals Inc. is expected to close next week after it obtained final clearance from the U.K...

UK Regulator Clears AstraZeneca's Alexion Deal

By Adria Calatayud The U.K. Competition and Markets Authority said Wednesday that it won't refer AstraZeneca PLC's anticipated acquisition of Alexion Pharmaceuticals Inc. for further...

Caelum & Alexion Present Additional Phase 2 Data Reinforcing Safety & Tolerability of CAEL-101 in AL Amyloidosis at the Europ...

- Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children & Adolescents with Paroxysmal Nocturnal Hemog...

 – With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH – – Approval based on interim results from Phase 3 study showing...

AstraZeneca Taps Alexion Executive for CFO Job -- Update

By Mark Maurer AstraZeneca PLC appointed an Alexion Pharmaceuticals Inc. executive as its new finance chief as the Covid-19 vaccine maker works to complete the acquisition of the company. The...

AstraZeneca Names Aradhana Sarin as Next CFO

By Adria Calatayud AstraZeneca PLC said Friday that it has appointed Aradhana Sarin, currently executive vice-president and chief financial officer of Alexion Pharmaceuticals Inc., as its next...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PMECPrimech Holdings Ltd
$ 1.08
(105.25%)
8.34M
BIMIBIMI International Medical Inc
$ 0.54
(38.11%)
36.78k
NUZENuZee Inc
$ 4.75
(28.38%)
1.03M
DALNDallasNews Corporation
$ 4.04
(23.93%)
28.77k
POWLPowell Industries Inc
$ 160.05
(20.11%)
87.73k
FGENFibroGen Inc
$ 0.525
(-49.03%)
1.16M
PEPGPepGen Inc
$ 10.97
(-35.39%)
21.69k
NARIInari Medical Inc
$ 42.28
(-18.86%)
37.35k
NCPLNetcapital Inc
$ 0.0689
(-16.99%)
936.91k
MGNXMacroGenics Inc
$ 4.40
(-16.19%)
71.71k
NVDANVIDIA Corporation
$ 106.39
(2.56%)
19.45M
SQQQProShares UltraPro Short QQQ
$ 9.55
(1.27%)
9.13M
PMECPrimech Holdings Ltd
$ 1.08
(105.25%)
8.34M
AMDAdvanced Micro Devices Inc
$ 147.43
(6.49%)
6.06M
MSFTMicrosoft Corporation
$ 395.998
(-6.37%)
5.51M

Your Recent History

Delayed Upgrade Clock